Why This Role Breaks Conventional Search Approaches
Most executive search firms approach VP Manufacturing as a standardised mandate. In cell and gene therapy, this framing misses the point entirely.
The VP Manufacturing in CGT is managing a process where the starting material is a patient's own cells, where batch sizes are one, where viral vector yields are inherently variable, and where the regulatory framework for ATMPs is still evolving across jurisdictions.
The Three Candidate Archetypes
The biologics crossover: Manufacturing leaders who have transitioned from conventional biologics into CGT. They bring operational discipline and GMP fluency but may underestimate the complexity of patient-specific manufacturing logistics.
The CGT native: Leaders who have grown up in the modality, typically through process development into manufacturing leadership. They understand the science deeply but may lack experience operating at commercial scale.
The CDMO veteran: Manufacturing leaders who have managed CGT programmes for multiple clients. They understand variability and multi-product environments but may struggle with the internal politics of a single-product sponsor company.
What Separates Good From Great
The VP Manufacturing candidates who succeed in CGT share a specific mindset: they treat manufacturing variability as an engineering problem, not an acceptable feature of the modality.
They have built systems to reduce vein-to-vein timelines, improve viral vector transfection efficiency, and implement process analytical technology that catches deviations early rather than at final release. They also understand that in CGT, manufacturing is not downstream of development - it is concurrent with it.
Compensation and Competition
US-based VP Manufacturing roles in CGT command base salaries of $260,000 to $340,000 with total compensation reaching $350,000 to $500,000, depending on company stage and equity participation. The equity component is significant at clinical-stage companies and can represent 30-50% of total compensation.
Critical Interview Questions
Three questions separate genuine CGT manufacturing leaders from candidates with adjacent but insufficient experience:
1. Describe a specific instance where you redesigned a manufacturing process to reduce vein-to-vein time and what the measurable outcome was.
2. How have you managed lot-to-lot variability in viral vector production and what systems did you implement to bring consistency?
3. Walk me through how you navigated a regulatory interaction where the authority questioned your manufacturing comparability data.
Candidates who answer these with specific, detailed examples rather than generalities are the ones worth shortlisting.